Cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the feasibility of an audiological monitoring program

INTERVIEW QUESTIONNAIRE FOR PHARMACISTS

Dear Pharmacists

We are delighted that you have agreed to participate and would like to thank you sincerely, as the information from this study can be used to help us understand the complexities associated with chemotherapy. The information that you provide will be treated with the strictest of confidence and please do not hesitate to ask us any questions that you may have during the course of the study. Contact details are reflected on the information and consent document.

INSTRUCTIONS
1. Please mark the appropriate answer to each question with an X, and give further detail if necessary.

2. Please answer all questions.
1. Do you dispense medication to patients on cancer chemotherapy?  
   - Yes  
   - No

2. How many times in the last month have you been consulted about drug interactions?  
   - <10  
   - 10-19  
   - 20-29  
   - 30-39  
   - 40-50

3. Does the hospital have a system that would allow you to identify patients at risk for a hearing loss?  
   - Yes  
   - No

4. Are you aware that certain chemotherapy drugs, for cancer, may cause hearing loss?  
   - Yes  
   - No

5. Do you alert oncology staff to patients who are at risk for an ototoxic hearing loss?  
   - Yes  
   - No

6. Do you consider the audiologist to be a part of the team who deals with patients with cancer?  
   - Yes  
   - No

7. Whose responsibility do you think it is to provide patients with information about the possible ototoxic effects of medication?  
   - Nurses  
   - Oncologists  
   - Pharmacists  
   - Audiologists

8. Whose responsibility do you think it is to refer patients at risk for a hearing loss to the ototoxicity monitoring program?  
   - Nurses  
   - Oncologists  
   - Pharmacists  
   - Audiologists

-----------------------------------THANK YOU FOR YOUR TIME AND CO-OPERATION-----------------------------------